# Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)

> **NCT02658981** · PHASE1 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 63 (actual)

## Conditions studied

- Glioblastoma
- Gliosarcoma
- Recurrent Brain Neoplasm

## Interventions

- **BIOLOGICAL:** Anti-LAG-3 Monoclonal Antibody BMS 986016
- **BIOLOGICAL:** Anti-PD-1
- **OTHER:** Pharmacological Study
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Anti-CD137

## Key facts

- **NCT ID:** NCT02658981
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-24
- **Primary completion:** 2022-04-30
- **Final completion:** 2023-10-03
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2023-10-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02658981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02658981, "Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02658981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*